Emily K. Larsen

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Ajay K. Gopal, Scott E. Smith et al. · Blood · 2016 · 395 citations · Full text

Medicine, Oncology, Pharmacology +13

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Ajay K. Gopal, Robert Chen, Scott E. Smith et al. · Blood · 2014 · 222 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS)

Eddy Barasch, John S. Gottdiener, Emily K. Larsen et al. · American Heart Journal · 2005 · 198 citations

Medicine, Cardiology, Geriatric Medicine +15